Neurocrine (NBIX) Biosciences announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia, or TD, severity and the impact of treatment with INGREZZA, or valbenazine, capsules in a real-world setting. In a subgroup analysis, nearly all patients with clinician-reported mild TD treated with INGREZZA experienced fewer uncontrolled movements, with most demonstrating symptom improvement within four weeks. Patients also showed widespread improvements in functional status, independence, ability to perform daily activities and ability to work. The findings are being presented at the American Psychiatric Association 2026 Annual Meeting, taking place May 16-20 in San Francisco. The analysis was based on a previously conducted clinician survey of patient chart data and clinician recall evaluating TD symptoms, functional impairment and improvement following treatment with INGREZZA. This analysis focused on a subgroup of patients with mild movement severity as rated by clinicians using global severity categories aligned with the Abnormal Involuntary Movement Scale. Prior to treatment, clinicians reported that mild TD movements impacted functional status in 90% of patients and independence in 84% of patients, with commonly affected areas including emotional, social, speech, dexterity and eating functions. Following the initiation of INGREZZA, nearly all patients with mild TD experienced clinician-reported improvements in uncontrolled movements. Of those patients, 86% improved in four weeks or less. Beyond improvements in uncontrolled movements, clinicians observed meaningful functional improvements across a range of daily life domains among patients with mild TD: For patients with impacted functional status almost all had improvement in overall functional status. Across all functional items, clinicians reported improvement in more than 90% of impacted patients, including those with impacted speech, dexterity, social status, emotional status and activities of daily living, such as eating and self-care.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
- Neurocrine completes acquisition of Soleno Therapeutics
- Aardvark Therapeutics downgraded to Underperform from Buy at BofA
- Neurocrine price target raised to $185 from $177 at JPMorgan
- Neurocrine price target raised to $155 from $140 at Truist
